key: cord-0759829-h2h7v0dn
authors: Pasha, Ahmed K.; McBane, Robert D.; Chaudhary, Rahul; Padrnos, Leslie J.; Wysokinska, Ewa; Pruthi, Rajiv; Ashrani, Aneel; Daniels, Paul; Sridharan, Meera; Wysokinski, Waldemar E.; Houghton, Damon E.
title: Timing of venous thromboembolism diagnosis in hospitalized and non-hospitalized patients with COVID-19
date: 2021-10-07
journal: Thromb Res
DOI: 10.1016/j.thromres.2021.09.021
sha: fd7869bf7661cf5eaf0eac7f8fbf45065abd2bb0
doc_id: 759829
cord_uid: h2h7v0dn

BACKGROUND: The reported incidence of venous thromboembolism (VTE) in COVID-19 patients varies widely depending on patient populations sampled and has been predominately studied in hospitalized patients. The goal of this study was to assess the evolving burden of COVID-19 and the timing of associated VTE events in a systems-wide cohort. METHODS: COVID-19 PCR positive hospitalized and non-hospitalized patients ≥18 years of age tested between 1/1/2020 through 12/31/2020 were retrospectively analyzed using electronic medical records from multiple states across the Mayo Clinic enterprise. Radiology reports within 90 days before and after confirmed COVID-19 diagnosis were examined for VTE outcomes using validated Natural Language Processing (NLP) algorithms. RESULTS: A 29-fold increased rate of VTE compared to the pre-COVID-19 period was noted during the first week following the first positive COVID-19 test (RR: 29.39; 95% CI 21.77-40.03). The rate of VTE steadily decreased and returned to baseline by the 6th week. Among 366 VTE events, most occurred during (n = 243, 66.3%) or after (n = 111, 30.3%) initial hospitalization. Only 11 VTE events were identified in patients who did not require hospitalization (3.0% of total VTE events). VTE and mortality increased with advancing age with a pronounced increased each decade in older patients. CONCLUSION: We observed a profoundly increased risk of VTE within the first week after positive testing for COVID-19 that returned to baseline levels after 6 weeks. VTE events occurred almost exclusively in patients who were hospitalized, with the majority of VTE events identified within the first days of hospitalization.

Severe acute respiratory syndrome (SARS) Coronavirus 2 (SARS-CoV-2), also known as COVID-19, has spread around the world causing significant morbidity and mortality 1 and has created significant challenges for health care systems and staff 2,3 .

COVID-19 daily mortality rates have exceeded those from cardiovascular disease and cancer 4 with a unique and alarming association with thrombosis 5 . Hematologic derangements that constitute a form of coagulopathy often manifest in the form of venous thromboembolism (VTE) [6] [7] [8] . Numerous reports from various countries have demonstrated a high incidence of VTE in COVID-19 patients [9] [10] [11] , however, there is a lot of heterogeneity reported in the risk of VTE 12 . Furthermore, the precise timing of VTE events as they relate to the diagnosis of COVID-19 has not been well studied. Much of the published data shows a high incidence of VTE in critically ill hospitalized patients, the group with the most severe presentations and most comorbidities. While managing VTE risk in hospitalized patients is essential, an exclusive focus on this setting limits the scope of the exploration of the relationship between COVID-19 and thrombosis.

The combination of referral bias of sicker individuals to tertiary referral centers, screening regimens to assess for asymptomatic VTE, examination of only hospitalized or intensive care patients, and nonstandard VTE definitions (including fistula thrombosis and superficial vein thrombosis) has led to some very high reported rates of venous thrombosis that may not be reflective of the population of patients more broadly who acquire COVID-19. VTE estimates in hospitalized patients range from 4.5-85% with pooled estimates from observational studies in meta-analyses estimating VTE incidence between 17-26% with noted concerns of heterogeneity and bias 13, 14 . One meta-analysis J o u r n a l P r e -p r o o f Journal Pre-proof of pulmonary emboli in hospitalized COVID-19 patients found the incidence to be much lower than others had reported (3.0%) when examining studies larger than 400 patients 15 and importantly, some studies have not demonstrated an overall increased thrombotic risk in COIVD-19 patients compared to other hospitalized patients 16 .

In this study, we evaluate VTE outcomes in COVID-19 infections across all patients (inpatients and outpatients) in the Mayo Clinic enterprise representing geographically diverse locations and different care settings (tertiary referral and regional hospitals). We further sought to evaluate the relative magnitude of risk in relation to baseline VTE rates as well as specifically examining timing of VTE and mortality as it relates to COVID-19 testing and hospitalization.

An electronic search of a unified data platform of laboratory records was performed from 1/1/2020 through 12/31/2020 to identify all Mayo Clinic enterprise patients at least 18 years or older with a COVID-19 positive PCR test.

Mayo Clinic enterprise consists of numerous outpatient and inpatient locations utilizing a common medical record system, including three tertiary referral centers (Rochester Minnesota, Phoenix Arizona, and Jacksonville Florida) and many regional Mayo Clinic were identified by analyzing the text from radiology reports. The VTE outcomes did not J o u r n a l P r e -p r o o f Journal Pre-proof include atypical sites of venous thrombosis (e.g. splanchnic vein thrombosis) or superficial thrombophlebitis. Natural language algorithms (NLP) to identify new/acute, or progressive PE and new/acute, or progressive DVT were created, validated, and applied to the text from the radiology report using the "simple NLP" program 18 Analysis. The primary outcome of interest was the first incident VTE after the first COVID-19 positive testing. The precise date of thrombus confirmation by imaging was determined by using the date of the first positive PE/DVT on CT/ultrasound (if multiple were positive). All radiology reports within 90 days before and after positive COVID-19 testing were examined. The VTE percentage and mortality rates were stratified and tabulated into age groups (rounded to the nearest decade). A histogram of events with COVID-19 testing date was created and no large spike in VTE diagnoses J o u r n a l P r e -p r o o f was observed in the 2 weeks before COVID-19 testing. Therefore, first VTE events occurring in a 90-day window before COVID-19 testing was used to calculate a baseline incident rate of VTE that reflected the inherent risk of the population based on age, gender, and other defined and undefined comorbidities. This baseline incidence rate of VTE was then compared to the incidence rate of VTE in weekly intervals after COVID-19 testing until rates returned to baseline levels. The relative increase in risk for VTE that could be attributed to COVID-19 infection and its sequelae was then determined.

Person-time follow-up for each weekly interval was readjusted to account for patients who died during that period. An incidence rate ratio (IRR) was calculated for each comparison with 95% confidence intervals. Based on the increase in the frequency of both VTE and death observed with increasing age, incidence rates and IRR were recalculated after stratifying age at 65 years.

To evaluate the cohort for possible biases associated with loss to follow-up, a subgroup analysis was performed evaluating VTE outcomes and death in a subset of patients residing only in counties contained within the Rochester Epidemiology Project.

Patients residing in these counties were identified using the patient-provided mailing address zip code. Residents of these counties with COVID-19 testing represent a local population of Mayo Clinic primary care patients where outcomes of VTE and death would, as a rule, be mostly uniformly captured and any escalation of care from a regional hospital to a tertiary hospital contain complete information. 

The central findings of our analysis are 1) an overall 29-fold increase in VTE events was noted during the first week after COVID-19 testing 2) VTE incidence and J o u r n a l P r e -p r o o f death increased with age with a pronounced increase each decade in older patients; 3) the frequency of VTE was much higher for hospitalized patients compared to nonhospitalized patients (5.6% vs 0.02%); 4) patients 65 years of age or older had a near 40-fold increased VTE rate in the first week; 5) VTE rate decreased to baseline pre-COVID-19 levels 6-7 weeks afterward.

Apart from hospitalized patients, the burden of thromboembolic disease in COVID-19 patients is not well established. For hospitalized patients, the frequency of VTE in this study was similar to some studies [19] [20] [21] [22] but significantly lower than others [23] [24] [25] . Patients not requiring hospital admission had a very low incidence of VTE (0.02%) which should be reassuring to providers and patients. This confirms the prevailing hypothesis that thromboembolic risk in COVID-19 closely mirrors the severity of illness.

These patients presumably had low severity of COVID-19 infection, minimal cytokine storm, were more ambulatory, would be less likely to have co-morbidities, and were younger. The results of the current study are consistent with the study of Piazza et al, where 715 COVID-19 patients managed as outpatients did not experience a VTE event.

In a study from Denmark using a nationwide population-based registry of COVID-19 patients, the overall 30 day incidence of VTE was 0.4% (9,460 patients) 26 baseline rate by the 6 th week. By the end of the first two weeks, the rate is reduced by half. This finding has not been reported previously in patients with COVID-19 infection.

The baseline, pre-COVID, rate of VTE was expectedly higher than population-based epidemiology studies 28 , consistent with data that shows that the population most susceptible to COVID-19 infection has more comorbidities and are "primed" for thromboembolic events. Recent data suggest a role for extended post-hospital prophylaxis in patients for about 4-6 weeks with a prophylactic dose of low molecular weight heparin or a direct oral anticoagulant (DOAC) for vulnerable patients. 29 .

However, in our study, the rate drops rapidly in the first few weeks following testing for COVID-19, suggesting 4-6 weeks of prophylaxis from time of diagnosis, rather than the time of hospital discharge might be more appropriate. Some institutions have implemented various doses of DVT prophylaxis for hospitalized COVID-19 patients 5 whereas others have instituted therapeutic anticoagulation over standard DVT prophylaxis 30, 31 . We identified that a sizable proportion of diagnosed VTE events (n=156) occurred either on admission or the next day. We find it extremely unlikely that any hospital anticoagulation strategy would reduce VTE events identified on the first or second day after hospitalization. These events almost certainly were "present on admission" and may not have been imaged promptly or imaging may not have been immediately available in the case of Duplex ultrasound. Standard pharmacologic DVT prophylaxis is not currently recommended in non-hospitalized patients 32 but these results highlight the importance of studies evaluating prophylactic anticoagulation strategies in high risk outpatients.

The frequency of VTE in COVID-19 patients following initial hospitalization in this study was 2.6% which is higher than others have reported 33, 34 . In the study by Ayra et al, 9 patients (0.48%) out of 1877 after hospital discharges were diagnosed with VTE within 42 days. When this VTE rate was compared to hospital discharges in the pre-COVID-19 era in 2019, the rate of VTE was not significantly different between both patient populations (OR 1.6; 95% CI 0.77-3.1; P=0.2). The higher frequency of VTE in the current study can in part be explained by the longer follow-up (90 days). Also, the subsequent VTE events post initial hospitalization, which may have occurred during possible second hospitalization were also included if they fell within the study period.

Data from this study also demonstrate overall shorter hospital length of stays in the last 4 months of 2020, possibly reflecting the increasing ability for some locations to finish remdesivir infusions as an outpatient when appropriate. This reduction in hospital length of stay, at a time we have identified as particularly high risk, would transition more events to the post-discharge setting that might have been inpatient events earlier in the pandemic as reported by other studies. This further reflects that the thrombotic risk in COVID-19 patients is high during acute illness 33 regardless of the need to remain in the hospital. Hence, merely a diagnosis of COVID-19 should not influence the decision for post-discharge extended prophylaxis. That decision needs to be individualized depending upon the patient's co-morbid conditions, additional VTE risk factors, and risk of bleeding, the way it is implemented following hospital discharge for any other medical illness 35 .

To our knowledge, this study represents the largest sample of COVID-19 patients evaluated for VTE events and contains a systems-wide cohort of hospitalized and non-J o u r n a l P r e -p r o o f hospitalized patients. The precise timing of VTE was known by utilizing a highly accurate NLP algorithm analyzing the imaging reports of each patient. While we would anticipate this would correlate with the timing of onset of the thrombotic event itself, the precise timing of symptoms of the thrombotic event cannot be ascertained from this study. Compared to traditional methods of VTE ascertainment, [International Classification of Disease (ICD) codes] our approach represents a significant improvement, bypassing the well-described inaccuracies known to occur with coding definitions and allows for a much more precise estimate of the timing of thrombosis. In general, upper extremity DVT is less well studied than "traditional" (ie lower

related hospitalized patients previously 36 . It is possible that this study missed VTE events that were diagnosed on a clinical basis alone due to concern for sending COVID-19 patients for imaging studies.

Unlike health care institutions that received an overwhelming influx of COVID-19 patients early in the pandemic leading unfortunately to rationing of healthcare resources, this was not the case among the institutions included in this study.

Furthermore, our previous studies have suggested that COVID-19 patients received at least an equal number of imaging studies compared to non-COVID-19 patients suggesting no hesitancy to order appropriate imaging tests 16 . Another strength of this study was the use of pre and post COVID-19 VTE rates within the same population. The J o u r n a l P r e -p r o o f calculated rate ratio is, therefore "self-adjusted" and does not require multivariable adjustment. The calculated rate ratio captures the entirety of VTE risk associated with COVID-19, encompassing the associated sequela from severe illness (hospitalization, organ failure, etc). An inherent limitation to our analysis is the retrospective nature of this study and possible loss to follow-up. The population selected reflected a cohort of patients who would seek their follow-up within the same interconnected healthcare system. This determination was verified by examining a subset of patients within a specific geographic region that demonstrated a similar outcome ascertainment.

Inclusion of only patients with PCR confirmed positive cases is both a strength and limitation, as some symptomatic patients who elected not to seek medical care could have been missed. Since symptoms of COVID-19 mimic many other viral presentations, utilizing only PCR confirmed cases ensures an accurate cohort. Another limitation was the inability to identify atypical site thrombosis, arterial thromboembolic events, and bleeding events. Using our NLP algorithm, we were not able to differentiate proximal from distal lower extremity DVT, which might alter the management. All VTE were identified by imaging in this study, therefore higher utilization of chest imaging for other purposes in hospitalized patients may have inflated the number of incidental pulmonary emboli as compared to the outpatient only population. Anticoagulation strategies (prophylactic or therapeutic) before and after COVID-19 testing could not be assessed in this study. However, the observed VTE rates should be concerning in light of the use of standard of care anticoagulant prophylaxis in hospitalized patients. Among hospitalized patients, the division between ICU and general ward could not be made J o u r n a l P r e -p r o o f reliably, and due to the inclusion of community and tertiary care hospitals, the heterogeneity between these patients would have likely significantly varied anyway.

In this large observational study, we found that there is a profoundly increased rate of VTE within the first week following positive COVID-19 testing, with the highest rate in patients 65 years and older. The rate then declined and returned to baseline by 

COVID-19 and its implications for thrombosis and anticoagulation

Moral outrage in COVID19-Understandable but not a strategy

COVID-19 and mental health: A review of the existing literature

COVID-19 as the Leading Cause of Death in the United States

Anticoagulation in COVID-19: A Systematic Review, Meta-analysis, and Rapid Guidance From Mayo Clinic

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review

COVID-19-associated coagulopathy: An exploration of mechanisms

Thrombo-inflammatory Biomarkers in COVID-19: Systematic Review and Meta-analysis of 17,052 patients

Acute Pulmonary Embolism in Patients with COVID-19 at CT Angiography and Relationship to d-Dimer Levels

High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients

Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in

Risk of venous thromboembolism in patients with COVID-19: A systematic review and meta-analysis. Res Pract Thromb Haemost

Venous thromboembolism in patients with COVID-19: Systematic review and meta-analysis

Incidence of VTE and Bleeding Among Hospitalized Patients With Coronavirus Disease 2019 A Systematic Review and Metaanalysis

Pulmonary Embolism Does Not Have an Unusually High Incidence Among Hospitalized COVID19 Patients

Macrovascular Thrombotic Events in a Mayo Clinic Enterprise-Wide Sample of Hospitalized COVID-19-Positive Compared With COVID-19-Negative Patients

Outcomes of COVID-19 With the Mayo Clinic Model of Care and Research

Creation of a simple natural language processing tool to support an imaging utilization quality dashboard

Registry of Arterial and Venous Thromboembolic Complications in Patients With COVID-19

Incidence of venous thromboembolism in coronavirus disease 2019: An experience from a single large academic center

Frequency of venous thromboembolism in 6513 patients with COVID-19: a retrospective study

Outcomes of COVID-19 in Patients With a History of Cancer and Comorbid Cardiovascular Disease

Incidence of venous thromboembolism in hospitalized patients with COVID-19

Acute Pulmonary Embolism Associated with COVID-19 Pneumonia Detected with Pulmonary CT Angiography

Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis

Venous thromboembolism and major bleeding in patients with COVID-19: A nationwide population-based cohort study

Incidence of 30-Day Venous Thromboembolism in Adults Tested for SARS-CoV-2 Infection in an Integrated Health Care System in Northern California

The epidemiology of venous thromboembolism

Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19

The effect of anticoagulation on clinical outcomes in novel Coronavirus (COVID-19) pneumonia in a U

American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19

COVID-19 and hypercoagulability in the outpatient setting

Postdischarge venous thromboembolism following hospital admission with COVID-19

☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.☐The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:J o u r n a l P r e -p r o o f